LiveSpo® NAVAX Nasal-Spray Probiotics: A New Approach in Supporting the Treatment of Rhinosinusitis and Otitis Media
HANOI, VIETNAM - Media OutReach Newswire - 19 May 2025 - LiveSpo® NAVAX – a nasal-spray probiotic product developed by Vietnamese scientists – has recently been published in the high-ranking international scientific journal Scientific Reports-Nature, recognizing its effectiveness in supporting the treatment of rhinosinusitis and otitis media in children. This marks the third consecutive study on the product published in a prestigious international scientific platform, reinforcing a promising new direction in non-antibiotic respiratory care.
The findings from the clinical study, conducted Thai Binh University of Medicine and Pharmacy in collaboration with other institutions, was published on January 27, 2025, in Scientific Reports-Nature, a renowned journal under the Nature Portfolio (UK). The results demonstrated significant effectiveness in children within just 3–7 days of use. Additionally, data also showed positive improvements in adults, highlighting the product's potential for broader application in the future.
The study was carried out from November 2023 to December 2024 with the participation of 126 patients, including both children and adults. Among children with acute rhinosinusitis and perforated acute otitis media, the treatment results were particularly notable: after 3 days of using LiveSpo® NAVAX, nasal congestion decreased by 68%, twice as much as the saline group. After 7 days, 97% of the children had no more nasal discharge, and 100% had no more ear discharge. The concentration of pathogenic bacteria Streptococcus pneumoniae in nasal and ear secretions dropped more than 1,200 times. Importantly, no side effects were recorded during the entire trial – even in children with weakened immune systems.
In the adult group with acute sinusitis, symptoms such as nasal congestion, facial pain, and purulent discharge improved significantly after 3 days of use – with reductions of 53%, 78%, and 61%, respectively. After 7 days, 91% of patients no longer experienced nasal discharge. Laboratory results showed a substantial reduction in pathogenic bacteria: Streptococcus pneumoniae decreased over 380-fold and Haemophilus influenzae decreased over 49,000-fold compared to the Control group receiving physiological saline
According to the research team, the effectiveness of LiveSpo® NAVAX origins from its ability to modulate local inflammatory responses and enhance mucosal immunity through the competitive biological mechanism of spore-forming Bacillus probiotics. Inflammatory markers such as IL-6, IL-8, and TNF-α significantly decreased, while levels of IgA – a key protective antibody at the mucosal surface – increased, contributing to the restoration of the nose and ear's natural defense barrier.
This study not only adds to the growing body of scientific evidence supporting LiveSpo® NAVAX's efficacy in respiratory care but also affirms Vietnam's biomedical research capabilities on the international scientific map. It paves the way for a safe, sustainable respiratory treatment alternative that reduces reliance on antibiotics – especially for vulnerable groups like children.
Dr. Nguyen Hoa Anh, Chairman and Founder of LiveSpo Pharma, shared:
"At LiveSpo, we prioritize the research and development of internationally standardized products, combining modern medicine with advanced probiotic technology to deliver safe and effective health solutions for the community – all with a vision of A Future Without Antibiotics."
References:
Khieu TH, Le DP, Nguyen BT, Ngo BT, Chu HT, Truong DM, Nguyen HM, Nguyen AH, Pham TD, Van Nguyen AT. Alleviating symptoms of paediatric acute rhinosinusitis and acute otitis media with otorrhea using nasal-spraying Bacillus probiotics: a randomized controlled trial. Sci Rep. 2025 Jan 27;15(1):3410. doi: 10.1038/s41598-025-87372-2. PMID: 39870748; PMCID: PMC11772584.
Hashtag: #LiveSpo
https://livespo.com
The issuer is solely responsible for the content of this announcement.
About LiveSpo Pharma
LiveSpo is an R&D, manufacturing, and distribution brand of Clinically Proven Medical Probiotics, leading in breakthrough technology, rapid effectiveness, and convenience, aiming for "A Future Without Antibiotics".
Our vision: In 2027, LiveSpo will have 1.5 million consumers who use Spore probiotics for digestive and respiratory health instead of antibiotics, with outstanding benefits and customer experiences. Established since 2010 by Dr. Nguyen Hoa Anh (Dr. ANH) and his colleagues, LiveSpo has remained steadfast in its belief that Live Probiotic Spores - Spobiotic - will pave the way to a future without antibiotics for everyone.
Hotline: 1800.088808
Website:
LiveSpo
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Khaleej Times
3 days ago
- Khaleej Times
Gut health revolution: Yakult's 90-year legacy in probiotic innovation
As the world comes together to celebrate World Milk Day, it's an opportune moment to highlight the role of functional dairy beverages in advancing everyday wellness. Among the most trusted names globally in this space is Yakult, a pioneering probiotic drink with a remarkable 90-year legacy rooted in scientific innovation and public health. Yakult was first developed in 1935 by Dr Minoru Shirota, a Japanese microbiologist who was driven by a simple yet powerful belief: that health begins in the gut. He succeeded in cultivating a unique strain of probiotics, Lactobacillus Casei Strain Shirota, which could reach the intestines alive and promote a healthy balance of gut bacteria. With this scientific breakthrough, he laid the foundation for Yakult, now enjoyed by 40 millions of people every day in more than 40 countries and regions. While traditional dairy products are celebrated for their calcium and protein content, Yakult brings an added value — a concentrated source of live probiotics in a small 80ml fermented skim milk bottle. These probiotics play a vital role in supporting digestion, enhancing immunity, and contributing to overall well-being — making Yakult a unique and essential addition to the modern dairy conversation. The legacy of Yakult extends beyond its probiotic content. Dr Shirota's vision was to make health accessible to everyone, and this philosophy continues to drive the company today. The iconic small bottle, recognisable worldwide, is a symbol of this commitment — a concentrated dose of beneficial bacteria designed for daily consumption. In 2025, Yakult proudly celebrates its 90th anniversary, marking nearly a century of commitment to science, education, and preventive health. This milestone reflects not only the success of a global brand but also the enduring relevance of its founding philosophy: 'A healthy intestine leads to a long life.' Gut health importance Over the decades, Yakult has invested heavily in research and public outreach, collaborating with health professionals, schools, and communities to spread awareness about the importance of gut health. In the Middle East, Yakult is not only expanding its market presence but also making a meaningful impact through educational outreach. One such initiative is the 'TeaTalks' programme — an engaging wellness series launched across the UAE aimed at raising awareness about gut health, probiotics, and preventive nutrition, particularly among women. Held in welcoming cafés and wellness spaces, TeaTalks seamlessly blend scientific knowledge with everyday lifestyle choices. These interactive sessions provide participants with the opportunity to connect directly with nutrition experts, gaining practical insights into how Yakult can play a role in supporting daily health and well-being. These sessions have also created a platform for meaningful dialogue on digestion, immunity, and wellness, reinforcing Yakult's commitment to community engagement and awareness, beyond just being a product on the shelf. On this World Milk Day, Yakult reminds us that dairy products can do more than nourish — they can heal, protect, and enhance quality of life. As global health trends shift toward prevention and holistic well-being, functional dairy beverages like Yakult are leading the way.
Zawya
7 days ago
- Zawya
Southern Hemisphere Innovation Showcase: BioGrowing's AKKBG-001 Debuts at Naturally Good Expo
SYDNEY, AUSTRALIA - Media OutReach Newswire - 29 May 2025 - BioGrowing, a leading Chinese probiotics innovator, marked its debut at the 2025 Naturally Good Expo in Sydney, showcasing its groundbreaking "Probiotic Family", including the star strain AKKBG-001. The event highlighted the company's commitment to advancing global health through cutting-edge research and multi-scenario applications of probiotics. Central of BioGrowing's exhibition was the unveiling of its independently developed AKKBG-001 strain. Demonstrated to support metabolic balance and immune enhancement, the strain's scalability in industrial production signals a milestone in China's probiotic R&D capabilities. During the expo,BioGrowing hosted a keynote session outlining global probiotic technology trends and introduced its core product lines addressing women's health, immune support, and oral health. BioGrowing's Flora-Focus® Women's Probiotic Series clinically validated formula combines three patented strains— Lactobacillus crispatus Lc-G22, Lactobacillus johnsonii LJ-G55, and Lacticaseibacillus rhamnosus Lr-G14—to inhibit fungal overgrowth and prevent vulvovaginal candidiasis (VVC), addressing growing regional health needs. Innovations such as the Flora-Focus® probiotic blend, OralBubble™ probiotic mirobubble lozenge, and OralFlash™ flash-melt probiotics drew significant attention. Company representatives also shared breakthroughs in proprietary strain screening, formulation technologies, and mechanistic research. "The true value of probiotics lies not only in solving health challenges but in driving sustainable industry progress," emphasized the Global Business Director. BioGrowing's science-driven approach, bolstered by collaborations with global academic institutions and eco-conscious production practices, continues to set benchmarks in the sector. Tailored to address Australia's prevalent gut health concerns, the Flora-Focus® range features clinically validated strains Lactobacillus acidophilus LA-G80 and Bifidobacterium animalis subsp. L actis BL-G101, proven to improve digestion, strengthen gut barriers, and stimulate beneficial fatty acid production. The patented YS1 strain further targets constipation relief with multi-layered microbiome support. Meanwhile, OralBubble™ and OralFlash™ redefine oral care through high-viability probiotics and flash-melt technology. With a "precision health" strategy, BioGrowing has developed a 9 category product matrix to meet diverse global needs, offering partners end-to-end solutions. Its expo booth emerged as a bridge connecting Chinese innovation with international markets, attracting distributors, health institutions, and media. "Australia represents a strategic foothold in our global expansion," stated the Global Business Director. "By integrating China's probiotic advancements into worldwide health ecosystems, we aim to empower every capsule with scientifically validated benefits." As BioGrowing continues to forge cross-border partnerships, its Sydney showcase underscores the rising influence of China's biotech sector in shaping the future of precision wellness. Hashtag: #BioGrowing The issuer is solely responsible for the content of this announcement. BioGrowing
Zawya
22-05-2025
- Zawya
VinFuture 2025: 1,705 nominations worldwide – twelvefold increase in nominating partners over five seasons
HANOI, VIETNAM - Media OutReach Newswire - 22 May 2025 - The VinFuture Prize, a global science and technology award, has officially concluded the nomination period for its fifth season with a total of 1,705 nominations submitted from around the world. Notably, the number of official nominating partners has seen exceptional growth, reaching 14,772 – more than a twelvefold increase from the 1,200 recorded in the inaugural season – underscoring the Prize's reputation as a global hub for scientific and intellectual excellence. This season marks a significant leap in both the quantity and quality of nominations, as demonstrated by the wide engagement of the esteemed global scientific community. Among the nominating partners, the majority are from the Americas (31%), followed by Europe (28.6%), Asia (26.8%), Africa (7.1%), and Oceania (6.5%). Among the 14,772 nominators, nearly half (7,240 experts) are affiliated with leading universities and research institutes worldwide. Institutions represented include Harvard University, the Massachusetts Institute of Technology, Stanford University (USA), the University of Cambridge, the University of Oxford (UK), the University of Melbourne (Australia), the University of Toronto (Canada), and the National University of Singapore (Singapore), among others. Notably, 1,395 nominators (9.4%) are scientists ranked among the top 2% most highly cited researchers globally, based on the prestigious list compiled by experts at Stanford University. The nominations for the 2025 award season continue to span a comprehensive range of critical fields essential to human well-being and global sustainable development. These include medicine and healthcare (36.7%); energy, transportation, and construction (17.8%); environment and earth sciences (17.8%); and agriculture and food (11.3%). These core fields mirror global science and technology priorities, attracting considerable attention from the international community. VinFuture's nominating partners play a vital role in identifying and nominating groundbreaking scientific innovations for well-deserved recognition. These innovations demonstrably benefit humanity on a global scale while also amplifying the VinFuture Prize's stature within the international scientific community. Driven by the Prize's profound mission and global vision, all nominators participate on a voluntary basis. In 2024, following a nomination by Professor Monica Lam, a leading computer scientist at Stanford University (USA), Mr. Jensen Huang, CEO and co-founder of NVIDIA, was honored as one of the 2024 VinFuture Grand Prize Laureates for his industry-driven contributions to the advancement of deep learning. Dr. Thai-Ha Le, Managing Director of the VinFuture Foundation, remarked: " Our five-year commitment to the mission of 'Science for Humanity' has establisheds VinFuture as an international beacon of scientific excellence and hope. The exponential growth in nominating partners and the exceptional quality of this year's nominations not only underscore the growing trust of the international scientific community in the Prize, but also highlight the urgent need for science and technology solutions to build a world where humanity thrives in harmony with a sustainable environment." The 2025 VinFuture pre-screening round will take place from May 26 to August 31. Its goal is to enable the 10-member Pre-Screening Committee to meticulously evaluate the most impactful and award-worthy nominations for advancement to the final round. In pursuit of scientific integrity, objectivity, and transparency, the Committee will assess the nominations through a rigorous evaluation process based on the highest international standards and core criteria. These criteria include the degree of scientific or technological advancement, the impact on people's lives, and the project's scale and sustainability. Within just five years, the VinFuture Prize has rapidly established its international stature and prestige, as evidenced by the growing list of laureates honored with prestigious global accolades. Notable examples include Dr. Katalin Karikó and Prof. Drew Weissman (laureates of the 2021 VinFuture Grand Prize and 2023 Nobel Prize in Physiology or Medicine); Dr. Demis Hassabis and Dr. John Jumper (laureates of the 2022 VinFuture Special Prize and 2024 Nobel Prize in Chemistry); Prof. Geoffrey Hinton (laureate of the 2024 VinFuture Grand Prize and 2024 Nobel Prize in Physics); Prof. Yoshua Bengio, Prof. Geoffrey Hinton, Mr. Jensen Huang, Prof. Yann LeCun, and Prof. Fei-Fei Li (laureates of the 2024 VinFuture Grand Prize and 2025 Queen Elizabeth Prize for Engineering); and Prof. Daniel Joshua Drucker, Prof. Joel Francis Habener, Prof. Jens Juul Holst, and Assoc. Prof. Svetlana Mojsov (laureates of the 2023 VinFuture Special Prize and 2025 Breakthrough Prize). Hashtag: #VinFuture The issuer is solely responsible for the content of this announcement. VinFuture The VinFuture Foundation, established on International Human Solidarity Day on December 20th, 2020, is a non-profit organization co-founded by billionaire Mr. Pham Nhat Vuong and his wife, Mrs. Pham Thu Huong. The Foundation's core activity is awarding the annual VinFuture Prize, which recognizes transformative scientific and technological innovations capable of making significant positive changes in the lives of millions of people worldwide. The VinFuture Prize consists of four prestigious awards presented each year. The most esteemed prize is the VinFuture Grand Prize, valued at US$3 million, making it one of the largest annual prizes globally. Additionally, there are three Special Prizes, each valued at US$500,000, specifically dedicated to honoring Women Innovators, Innovators from Developing Countries, and Innovators with Outstanding Achievements in Emerging Fields. VinFuture
